Azenta (AZTA)
(Delayed Data from NSDQ)
$53.67 USD
+0.85 (1.61%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $53.71 +0.04 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AZTA 53.67 +0.85(1.61%)
Will AZTA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AZTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZTA
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
AZTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?
Other News for AZTA
What's Driving ICU Medical Inc's Surprising 15% Stock Rally?
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
Azenta to Participate in the Jefferies Global Healthcare Conference
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Robotics Stocks
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK